RxDoctor Payments Data

Hernando Jose Cordero Fernandez de Cordova, MD

Pulmonary Disease · Miami Beach, FLNPI 1770969859

Payments from drug & device makers

$2,743in general payments, 2019–2025

Across 88 payments — averaging $31.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$555
  • GSK$522
  • AstraZeneca$493
  • Inari Medical, Inc.$174
  • Takeda Pharmaceuticals U.S.A., Inc.$155
  • Mylan Specialty L.p.$147
  • plus $698 from 13 others

What the payments were for

  • Food & beverage$2,64396%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,743 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$148,563
Medicare patients
314
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate18$236,193
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$58,643
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$30,421
Incruse ElliptaUmeclidinium Bromide75$28,135
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,642
SymbicortBudesonide/Formoterol Fumarate24$7,697
Spiriva RespimatTiotropium Bromide12$7,499
EliquisApixaban11$6,695
Ventolin HfaAlbuterol Sulfate22$1,274
Albuterol Sulfate HfaAlbuterol Sulfate48$854
Wixela InhubFluticasone Propion/Salmeterol15$728
Ipratropium Bromide31$484
Montelukast Sodium24$271
Fluticasone Propionate16$165
Prednisone37$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$57$243,69230 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$522$117,200216 claims
AstraZenecaBreztri Aerosphere, Symbicort$493$19,33942 claims
PfizerEliquis$22$6,69511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →